MS
RCKT icon

Maven Securities’s Rocket Pharmaceuticals RCKT Stock Holding History

Maven Securities’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-170,000
Closed -$7.5M – 1237
2021
Q2 		$7.5M Buy
170,000
+5,166
+3% +$224K 0.3% 55
2021
Q1 		$7.31M Buy
164,834
+64,834
+65% +$3.56M 0.33% 51
2020
Q4 		$5.62M Buy
+100,000
New +$3.65M 0.56% 44
2020
Q1 		– Sell
-31,000
Closed -$729K – 417
2019
Q4 		$729K Buy
+31,000
New +$518K 0.07% 213

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Maven Securities's RCKT Position: Q3 2021 in Review

Maven Securities sold out of Rocket Pharmaceuticals (RCKT) in Q3 2021, closing a stake of 170,000 shares — an estimated $7.5M sold.

Maven Securities first reported a position in RCKT in Q4 2019 and held it in 4 quarters. The position peaked at $7.5M in Q2 2021. 146 funds tracked by Wall St. Rank hold RCKT as of Q3 2021.

  • Maven Securities reported no remaining Rocket Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 170,000 Rocket Pharmaceuticals shares in Q3 2021, an estimated $7.5M.
  • Maven Securities first reported a position in Rocket Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Maven Securities's Rocket Pharmaceuticals position peaked at $7.5M in Q2 2021.
  • 146 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.